Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.

George E DaileyTerry A DexMichelle RobertsMinzhi LiuGraydon S Meneilly

Published in: Journal of diabetes (2019)

Add-on therapy with lixisenatide in non-frail patients aged ≥70 years with T2D uncontrolled with BI is effective, safe, and well tolerated and should be considered in this population.

Keyphrases

end stage renal disease
ejection fraction
type diabetes
newly diagnosed
chronic kidney disease
peritoneal dialysis
stem cells
adipose tissue
skeletal muscle
mesenchymal stem cells
patient reported outcomes
insulin resistance
replacement therapy